Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial is studying how well selumetinib works in treating patients with
recurrent or refractory acute myeloid leukemia. Selumetinib may stop the growth of cancer by
blocking some of the enzymes needed for cell growth